PeerVoice Clinical Pharmacology Audio

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH

Antonella Castagna, MD - Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would You Do?

David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms

Jai Radhakrishnan, MD, MS / Ladan Zand, MD - Investigating Novel Approaches and Unmet Needs in the Management of Glomerular Diseases

Kieran McCafferty, MB BChir, MRCP, MD (res) / Shelley Zieroth, MD, FRCPC, FHFSA (hon) - Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease and Heart Failure

Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers

James F. Howard Jr, MD - Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors

Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?

George L. Bakris, MD, MA - Step-by-Step: Setting a Course for Managing CKD and T2DM With Nonsteroidal MRAs

Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?

Nizar Mahlaoui, MD, MPH, PhD - Simplifying Patient-Integrated Care for Those Requiring Immunoglobulin Therapy: Making Smart Moves with Automated and Digital Technology

Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma